Decopharma has been acquired by CTT
July 2025 — Decopharma has been acquired by CTT – Correios de Portugal, strengthening its position as a national reference in pharmaceutical logistics solutions. This strategic transaction marks an important step in the consolidation of the specialized logistics sector in Portugal, combining Decopharma’s expertise in healthcare logistics with CTT’s robust infrastructure and growth potential.
Decopharma provides end-to-end logistics services for the pharmaceutical and healthcare sectors, covering medicines such as over-the-counter products (OTC), nutraceuticals, cosmetics and veterinary items, as well as medical devices including hospital equipment, consumables and laboratory supplies. With a team of around 30 employees, the company manages the entire logistics chain — from goods reception and storage to quality control, order processing and distribution.
CTT – Correios de Portugal is a leading provider of integrated logistics and distribution services, offering parcel delivery, express shipping and e-commerce solutions. Backed by a nationwide infrastructure and specialized subsidiaries like CTT Expresso, the company enables efficient last-mile delivery and supply chain operations for businesses across various sectors.
Our role in the transaction
Oaklins’ team in Portugal advised the shareholders of Decopharma in this transaction.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreSynergia and Bolster have secured acquisition financing for Life & Mobility
Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.
Learn more